Status:
TERMINATED
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to characterize the baseline variability of a panel of tissue (tumor and adjacent) and blood-based biomarkers obtained from participants with hepatocellular carcinoma (HCC...
Eligibility Criteria
Inclusion
- Diagnosed with HCC.
- Candidate for surgical resection or has no contraindications to MRI procedures.
Exclusion
- Prior loco-regional treatment of tumor, unless there is untreated tumor present representing a distinct untreated nodule.
- Confirmed or suspected diagnosis of fibrolamellar HCC, mixed HCC/cholangiocarcinoma or metastatic tumor.
- Had a liver transplant.
Key Trial Info
Start Date :
April 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01521780
Start Date
April 1 2012
End Date
November 1 2012
Last Update
November 2 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.